我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
29
5 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
2012
进行中（未招募）
5
17.2%
已完成
15
51.7%
招募中
终止
3
10.3%
撤回
1
3.5%
暂无批准数据
- Aurinia Pharmaceuticals and Teva Pharmaceuticals reached a settlement resolving patent litigation over Teva's proposed generic 7.9 mg voclosporin oral capsules. - Teva stipulated that Aurinia's U.S. Patent Nos. 10,286,036 and 11,622,991 are valid, enforceable, and would be infringed by its generic product. - Under the agreement, Teva may not launch its generic voclosporin before December 7, 2036, contingent on FDA approval. - Aurinia's patent infringement actions continue against DifGen, Dr. Reddy's, Hikma, Lotus/Sandoz, and Zydus in the District of New Jersey.
